We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter Est. Return
+24.54%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$787M
AUM Growth
+$143M
(+22%)
Cap. Flow
+$36.2M
Cap. Flow % of AUM
Cap. Flow %
4.61%
Top 10 Holdings %
Top 10 Hldgs %
62.09%
Holding
40
New
7
Increased
12
Reduced
8
Closed
4
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$46.3M |
| 2 |
ZEAL
Zealand Pharma A/S American Depositary Shares
ZEAL
|
+$18.8M |
| 3 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
+$18.6M |
| 4 |
Intra-Cellular Therapies Inc.
ITCI
|
+$13.9M |
| 5 |
Kura Oncology
KURA
|
+$12.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blueprint Medicines
BPMC
|
+$31.2M |
| 2 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$17.8M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$17.5M |
| 4 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$16M |
| 5 |
Cytokinetics
CYTK
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.39% |
| 2 | Miscellaneous | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Array Biopharma Inc
ARRY
| $78.8M | 10.01% |
6,402,525
+342,900
| +6% | +$3.18M |
2013 Q2
17 quarters
|
|
|
2
DELISTED
Blueprint Medicines
BPMC
| $70.2M | 8.92% |
1,007,354
-584,292
| -37% | -$31.2M |
2015 Q2
9 quarters
|
|
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $56.3M | 7.16% |
7,587,416
-661,000
| -8% | -$5.49M |
2013 Q2
17 quarters
|
|
4
AnaptysBio
ANAB
$1.45B
| $48.2M | 6.13% |
1,379,134
-280,066
| -17% | -$7.55M |
2017 Q1
2 quarters
|
|
|
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $46.2M | 5.88% |
3,135,289
+1,278,394
| +69% | +$18.6M |
2014 Q3
12 quarters
|
|
6
Crescent Biopharma
CBIO
$517M
| $45.2M | 5.74% |
32,299
+2,597
| +9% | +$3.05M |
2016 Q2
5 quarters
|
|
|
7
Ironwood Pharmaceuticals
IRWD
$796M
| $44.5M | 5.65% |
+3,367,080
| New | +$46.3M |
2017 Q3
0 quarters
|
|
8
CytomX Therapeutics
CTMX
$432M
| $40.5M | 5.15% |
2,230,898
+203,900
| +10% | +$3.18M |
2015 Q4
7 quarters
|
|
9
DELISTED
Xoma
XOMA
| $29.5M | 3.75% |
1,502,800
| – | – |
2016 Q4
3 quarters
|
|
10
BioLineRX
BLRX
$7.57M
| $29.1M | 3.7% |
43,326
+14,159
| +49% | +$8.79M |
2017 Q1
2 quarters
|
|
|
CTIC
11
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $27.4M | 3.49% |
8,596,357
| – | – |
2015 Q3
8 quarters
|
|
|
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
| $22M | 2.79% |
238,386
-225,000
| -49% | -$17.5M |
2017 Q1
2 quarters
|
|
|
13
Kura Oncology
KURA
$673M
| $20.2M | 2.57% |
+1,353,846
| New | +$12.7M |
2017 Q3
0 quarters
|
|
|
OMED
14
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| – | – |
-4,400,289
| Closed | -$17.8M | – |
|
|
ZEAL
15
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
| $19.2M | 2.44% |
+1,000,000
| New | +$18.8M |
2017 Q3
0 quarters
|
|
|
16
Cytokinetics
CYTK
$7.83B
| $18M | 2.29% |
1,241,021
-749,300
| -38% | -$10.2M |
2013 Q2
17 quarters
|
|
17
Palvella Therapeutics
PVLA
$2.47B
| $17.2M | 2.19% |
37,332
-6,317
| -14% | -$2.7M |
2016 Q2
5 quarters
|
|
18
DELISTED
Regulus Therapeutics
RGLS
| $16.2M | 2.06% |
107,910
+80,586
| +295% | +$10.1M |
2017 Q1
2 quarters
|
|
|
19
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15M | 1.91% |
+950,000
| New | +$13.9M |
2017 Q3
0 quarters
|
|
20
DELISTED
Forte Biosciences
FBRX
| $13.2M | 1.68% |
2,835
-576
| -17% | -$2.57M |
2017 Q2
1 quarter
|
|
|
CASC
21
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $12.8M | 1.63% |
3,133,224
| – | – |
2013 Q2
17 quarters
|
|
|
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $11M | 1.4% |
163,169
+9,323
| +6% | +$534K |
2017 Q2
1 quarter
|
|
23
Xenon Pharmaceuticals
XENE
$4.01B
| $10.6M | 1.35% |
3,588,830
+70,000
| +2% | +$217K |
2014 Q4
11 quarters
|
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $10.5M | 1.33% |
7,866,108
| – | – |
2016 Q2
5 quarters
|
|
25
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $9.11M | 1.16% |
7,917
| – | – |
2014 Q4
11 quarters
|
|
Similar funds
LFCM
AC
BVF Inc's Q3 2017 Portfolio in Review
As of Q3 2017, BVF Inc held 40 positions worth $787M, up 22% from $644M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
BVF Inc deployed $36.2M of net new capital in Q3 2017, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was Ironwood Pharmaceuticals: 3,367,080 shares worth $44.5M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Blueprint Medicines, an estimated $31.2M trimmed.
- BVF Inc's largest Q3 2017 buy was Ironwood Pharmaceuticals: 3,367,080 shares worth $44.5M.
- BVF Inc added most to Concert Pharmaceuticals, Inc. in Q3 2017, an estimated $18.6M increase.
- BVF Inc's biggest Q3 2017 reduction was Blueprint Medicines, cutting an estimated $31.2M.
- BVF Inc fully exited OncoMed Pharmaceuticals, Inc. in Q3 2017, selling an estimated $17.8M.
- BVF Inc's ten largest holdings make up 62% of its $787M portfolio in Q3 2017.
- BVF Inc opened 7 new positions and closed 4 in Q3 2017.
- BVF Inc's portfolio value rose 22% quarter-over-quarter to $787M.
Based on BVF Inc's 13F filing for Q3 2017, filed 14 Nov 2017.